Pub Date : 2026-02-09DOI: 10.1007/s00259-026-07780-y
Florian Perozziello, Grégoire Robert, Marie Meyer, Eva Jambon, Franck Bladou, Mokrane Yacoub, Frédéric Lamare, Delphine Vimont, Nicolas Balamoutoff, Elif Hindié, Clément Morgat
{"title":"Prospective head-to-head comparison of [<sup>68</sup>Ga]Ga-RM2 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in newly diagnosed patients with intermediate-risk localized prostate cancer.","authors":"Florian Perozziello, Grégoire Robert, Marie Meyer, Eva Jambon, Franck Bladou, Mokrane Yacoub, Frédéric Lamare, Delphine Vimont, Nicolas Balamoutoff, Elif Hindié, Clément Morgat","doi":"10.1007/s00259-026-07780-y","DOIUrl":"https://doi.org/10.1007/s00259-026-07780-y","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-09DOI: 10.1007/s00259-026-07770-0
Kaat Spoormans, Lara Struelens, Michel Koole, Melissa Crabbé
{"title":"From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [<sup>177</sup>Lu]Lu-DOTATATE and [<sup>161</sup>Tb]Tb-DOTATATE.","authors":"Kaat Spoormans, Lara Struelens, Michel Koole, Melissa Crabbé","doi":"10.1007/s00259-026-07770-0","DOIUrl":"https://doi.org/10.1007/s00259-026-07770-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1007/s00259-025-07733-x
Lukas Kessler, Wibke Tonscheidt, Kai Nassenstein, Stephan Settelmeier, Alexander Carpinteiro, H Christian Reinhardt, Tim Hagenacker, Lale Umutlu, Christoph Kleinschnitz, Simon Wernhart, Lars Michel, Michal K Chodyla, Benedikt M Schaarschmidt, Thomas-Wilfried Schlosser, Wolfgang P Fendler, Francesco Barbato, Maria Papathanasiou, Christoph Rischpler, Ken Herrmann, Tienush Rassaf, David Kersting
Purpose: Positron emission tomography (PET) with amyloid-binding tracers was shown to have high sensitivity for the detection of both transthyretin (ATTR) and light-chain (AL) cardiac amyloidosis (CA). Recent studies describe prognostic value of imaging biomarkers from bone scintigraphy and 18F-Florbetapir. The aim of this study was to evaluate the value of imaging biomarkers from 18F-Florbetaben PET, cardiac magnetic resonance (CMR), and echocardiography imaging for prediction of major adverse cardiac events (MACE) in comparison to serum biomarkers in patients with different types of CA.
Methods: Patients who underwent cardiac 18F-Florbetaben PET/MRI were prospectively enrolled and received clinical follow-up for up to 36 months and MACE were reported (NCT07154381). Scans were reported by two blinded, nuclear medicine physicians. Imaging biomarkers including average retention index (RI), T1 mapping/ extracellular volume (ECV) and serological markers were estimated and their association with MACE free survival was analyzed.
Results: Twenty-one patients with confirmed CA were enrolled. MACEs were reported in 14 of 21 patients (66.7%). Higher average RI was the only imaging biomarker that was a significant predictor for MACE in uni- and multivariate analysis (HR = 4.02, 95%CI: 1.25-12.9, p < 0.05). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was a significant predictor in uni- but not in multivariate analysis. Patients with AL-CA showed a higher rate of MACE than patients with other subtypes.
Conclusion: Integrated 18F-Florbetaben PET/MR allows diagnosis, subtype differentiation and outcome predication of CA. The average RI was the only significant and independent prognostic imaging biomarker of MACE. Future prospective studies are warranted to investigate benefits for patient management and risk assessment in larger cohorts.
{"title":"Prognostic parameters and detection of cardiac amyloidosis with hybrid <sup>18</sup>F-Florbetaben-PET/MRI: an exploratory observational study.","authors":"Lukas Kessler, Wibke Tonscheidt, Kai Nassenstein, Stephan Settelmeier, Alexander Carpinteiro, H Christian Reinhardt, Tim Hagenacker, Lale Umutlu, Christoph Kleinschnitz, Simon Wernhart, Lars Michel, Michal K Chodyla, Benedikt M Schaarschmidt, Thomas-Wilfried Schlosser, Wolfgang P Fendler, Francesco Barbato, Maria Papathanasiou, Christoph Rischpler, Ken Herrmann, Tienush Rassaf, David Kersting","doi":"10.1007/s00259-025-07733-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07733-x","url":null,"abstract":"<p><strong>Purpose: </strong>Positron emission tomography (PET) with amyloid-binding tracers was shown to have high sensitivity for the detection of both transthyretin (ATTR) and light-chain (AL) cardiac amyloidosis (CA). Recent studies describe prognostic value of imaging biomarkers from bone scintigraphy and <sup>18</sup>F-Florbetapir. The aim of this study was to evaluate the value of imaging biomarkers from <sup>18</sup>F-Florbetaben PET, cardiac magnetic resonance (CMR), and echocardiography imaging for prediction of major adverse cardiac events (MACE) in comparison to serum biomarkers in patients with different types of CA.</p><p><strong>Methods: </strong>Patients who underwent cardiac <sup>18</sup>F-Florbetaben PET/MRI were prospectively enrolled and received clinical follow-up for up to 36 months and MACE were reported (NCT07154381). Scans were reported by two blinded, nuclear medicine physicians. Imaging biomarkers including average retention index (RI), T1 mapping/ extracellular volume (ECV) and serological markers were estimated and their association with MACE free survival was analyzed.</p><p><strong>Results: </strong>Twenty-one patients with confirmed CA were enrolled. MACEs were reported in 14 of 21 patients (66.7%). Higher average RI was the only imaging biomarker that was a significant predictor for MACE in uni- and multivariate analysis (HR = 4.02, 95%CI: 1.25-12.9, p < 0.05). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was a significant predictor in uni- but not in multivariate analysis. Patients with AL-CA showed a higher rate of MACE than patients with other subtypes.</p><p><strong>Conclusion: </strong>Integrated <sup>18</sup>F-Florbetaben PET/MR allows diagnosis, subtype differentiation and outcome predication of CA. The average RI was the only significant and independent prognostic imaging biomarker of MACE. Future prospective studies are warranted to investigate benefits for patient management and risk assessment in larger cohorts.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To evaluate the usefulness of [18F]AlF-labeled fibroblast activation protein inhibitor (FAPI), chelated with NOTA (denoted as [18F]AlF-NOTA-FAPI), positron emission tomography/computed tomography (PET/CT) for radiotherapy planning in lung cancer, we compared it with contrast-enhanced CT (CE-CT) and [18F]FDG PET/CT.
Materials and methods: In this secondary analysis of a prospective trial, patients with stage I-III lung cancer who underwent [18F]AlF-NOTA-FAPI and CE-CT or [18F]FDG PET/CT scans within 2 weeks were selected. Gross tumor volume (GTV), clinical tumor volume (CTV), and planning tumor volume (PTV) were drawn for the primary tumor (GTVp) and involved lymph nodes (GTVnd) based on CE-CT, [18F]AlF-NOTA-FAPI PET/CT and [18F]FDG PET/CT. Organs at risk were evaluated and compared in intensity-modulated radiation therapy (IMRT) and intensity-modulated proton therapy (IMPT) plans.
Results: Fifty-one patients (median age, 64 years; 38 males [74.5%]) were evaluated. Statistically significant differences in GTVs based on CE-CT, [18F]AlF-NOTA-FAPI PET/CT, and [18F]FDG PET/CT were found between each pair (all P < 0.05), except that no difference in GTVp was found between [18F]AlF-NOTA-FAPI and [18F]FDG PET/CT (P = 0.558). CE-CT-based GTVp values were significantly larger than those based on [18F]FDG PET/CT and [18F]AlF-NOTA-FAPI PET/CT due to the presence of obstructive pneumonia (n = 18; all P < 0.05). PTVall-IMRT based on CE-CT (351.98 ± 26.87) was significantly larger than that based on [18F]AlF-NOTA-FAPI PET/CT (329.98 ± 26.21; P = 0.03). PTVall-IMPT based on CE-CT (212.74 ± 18.73) was significantly larger than those based on [18F]FDG PET/CT (204.26 ± 19.34) and [18F]AlF-NOTA-FAPI PET/CT (196.99 ± 18.38), with P-values of 0.046 and 0.011, respectively. For IMRT, [18F]AlF-NOTA-FAPI PET/CT-based plans significantly reduced the radiation doses received by the heart, contralateral lung, and both lungs (all P < 0.05).
Conclusion: [18F]AlF-NOTA-FAPI PET/CT shows promise as a valuable tool for radiotherapy planning in lung cancer, providing accurate target delineation and improved sparing of critical organs.
Trial registration: This study was approved by the Clinical Research Ethics Committee of our institution.
{"title":"Value of [<sup>18</sup>F]AlF-NOTA-FAPI PET/CT in guiding radiotherapy planning for stage I-IIIC lung cancer: A comparison with contrast-enhanced CT and [<sup>18</sup>F]FDG PET/CT.","authors":"Jingjie Qin, Chengqiang Li, Yong Huang, Yuqin Jin, Xiaoshan Liu, Xudong Hu, Jian Zhu, Junya San, Hongbo Wu, Xue Meng, Jinming Yu, Yuchun Wei","doi":"10.1007/s00259-025-07753-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07753-7","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the usefulness of [<sup>18</sup>F]AlF-labeled fibroblast activation protein inhibitor (FAPI), chelated with NOTA (denoted as [<sup>18</sup>F]AlF-NOTA-FAPI), positron emission tomography/computed tomography (PET/CT) for radiotherapy planning in lung cancer, we compared it with contrast-enhanced CT (CE-CT) and [<sup>18</sup>F]FDG PET/CT.</p><p><strong>Materials and methods: </strong>In this secondary analysis of a prospective trial, patients with stage I-III lung cancer who underwent [<sup>18</sup>F]AlF-NOTA-FAPI and CE-CT or [<sup>18</sup>F]FDG PET/CT scans within 2 weeks were selected. Gross tumor volume (GTV), clinical tumor volume (CTV), and planning tumor volume (PTV) were drawn for the primary tumor (GTVp) and involved lymph nodes (GTVnd) based on CE-CT, [<sup>18</sup>F]AlF-NOTA-FAPI PET/CT and [<sup>18</sup>F]FDG PET/CT. Organs at risk were evaluated and compared in intensity-modulated radiation therapy (IMRT) and intensity-modulated proton therapy (IMPT) plans.</p><p><strong>Results: </strong>Fifty-one patients (median age, 64 years; 38 males [74.5%]) were evaluated. Statistically significant differences in GTVs based on CE-CT, [<sup>18</sup>F]AlF-NOTA-FAPI PET/CT, and [<sup>18</sup>F]FDG PET/CT were found between each pair (all P < 0.05), except that no difference in GTVp was found between [<sup>18</sup>F]AlF-NOTA-FAPI and [<sup>18</sup>F]FDG PET/CT (P = 0.558). CE-CT-based GTVp values were significantly larger than those based on [<sup>18</sup>F]FDG PET/CT and [<sup>18</sup>F]AlF-NOTA-FAPI PET/CT due to the presence of obstructive pneumonia (n = 18; all P < 0.05). PTVall-IMRT based on CE-CT (351.98 ± 26.87) was significantly larger than that based on [<sup>18</sup>F]AlF-NOTA-FAPI PET/CT (329.98 ± 26.21; P = 0.03). PTVall-IMPT based on CE-CT (212.74 ± 18.73) was significantly larger than those based on [<sup>18</sup>F]FDG PET/CT (204.26 ± 19.34) and [<sup>18</sup>F]AlF-NOTA-FAPI PET/CT (196.99 ± 18.38), with P-values of 0.046 and 0.011, respectively. For IMRT, [<sup>18</sup>F]AlF-NOTA-FAPI PET/CT-based plans significantly reduced the radiation doses received by the heart, contralateral lung, and both lungs (all P < 0.05).</p><p><strong>Conclusion: </strong>[<sup>18</sup>F]AlF-NOTA-FAPI PET/CT shows promise as a valuable tool for radiotherapy planning in lung cancer, providing accurate target delineation and improved sparing of critical organs.</p><p><strong>Trial registration: </strong>This study was approved by the Clinical Research Ethics Committee of our institution.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1007/s00259-026-07791-9
Roberto Colli, Jakob Nilsson
{"title":"A distinctive “Shotgun-like” 18F-FDG PET uptake pattern in disseminated cutaneous sarcoidosis responding to TNFα inhibitors","authors":"Roberto Colli, Jakob Nilsson","doi":"10.1007/s00259-026-07791-9","DOIUrl":"https://doi.org/10.1007/s00259-026-07791-9","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"44 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1007/s00259-026-07789-3
Yuzhen Jin, Yi Yang, Yue Yang, Jinhui Yang, Lu Hao, Chuxing Hu, Tingting Long, Shuo Hu
{"title":"Development and validation of a CXCR4-targeted 68 Ga-Pentixafor PET/CT–based nomogram for predicting postoperative clinical success in unilateral primary aldosteronism","authors":"Yuzhen Jin, Yi Yang, Yue Yang, Jinhui Yang, Lu Hao, Chuxing Hu, Tingting Long, Shuo Hu","doi":"10.1007/s00259-026-07789-3","DOIUrl":"https://doi.org/10.1007/s00259-026-07789-3","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"5 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1007/s00259-025-07711-3
Chunhui Wu, Ahmad Kurniawan, Zihe Ming, Ines F Antunes, Walter Noordzij, Andor Glaudemans, Bart Cornelissen
{"title":"Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.","authors":"Chunhui Wu, Ahmad Kurniawan, Zihe Ming, Ines F Antunes, Walter Noordzij, Andor Glaudemans, Bart Cornelissen","doi":"10.1007/s00259-025-07711-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07711-3","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1007/s00259-026-07785-7
Omer Aras, Kezban Berberoğlu
{"title":"First-in-human tandem Terbium-161 and Actinium-225 PSMA radioligand therapy in metastatic castration-resistant prostate cancer.","authors":"Omer Aras, Kezban Berberoğlu","doi":"10.1007/s00259-026-07785-7","DOIUrl":"https://doi.org/10.1007/s00259-026-07785-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1007/s00259-025-07710-4
Sarah Beishan Tai, Wei Ming Chua, Cherie Wei Qi Ng, Maria Noviani, Wei Ping Tham, Seyed Ehsan Saffari, Winnie Wing Chuen Lam, David Chee Eng Ng, Adrian Shoen Choon Seng Low, Wanying Xie, Andrea Hsiu Ling Low
{"title":"Exploratory evaluation of early 68Ga-FAPI-46 PET/CT volume-based parameters in systemic sclerosis-associated interstitial lung disease","authors":"Sarah Beishan Tai, Wei Ming Chua, Cherie Wei Qi Ng, Maria Noviani, Wei Ping Tham, Seyed Ehsan Saffari, Winnie Wing Chuen Lam, David Chee Eng Ng, Adrian Shoen Choon Seng Low, Wanying Xie, Andrea Hsiu Ling Low","doi":"10.1007/s00259-025-07710-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07710-4","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"57 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号